Gastrointestinal

GERD: outpatient stepwise management and red flags

Clinical Overview and When to Suspect GERD

— Prevalence ~20% of US adults; one of the most common outpatient GI complaints in primary care

— Risk factors: obesity (especially central adiposity), hiatal hernia, pregnancy, tobacco, alcohol, scleroderma, delayed gastric emptying, certain medications (CCBs, nitrates, anticholinergics, bisphosphonates, NSAIDs aggravate mucosa)

— Transient lower esophageal sphincter relaxations (TLESRs) are the dominant mechanism, not low resting LES tone

— Hiatal hernia disrupts the crural diaphragm component of the antireflux barrier

— Impaired esophageal acid clearance + delayed gastric emptying amplify mucosal exposure

— Classic: heartburn (retrosternal burning, postprandial, worse supine/bending) and/or regurgitation

— Extraesophageal/atypical: chronic cough, laryngitis, hoarseness, dental erosions, asthma exacerbation, non-cardiac chest pain — but only attribute to GERD after cardiac and pulmonary causes excluded

— Sleep disturbance from nocturnal reflux is a key Step 3 driver of escalation

Definition: Gastroesophageal reflux disease (GERD) is symptomatic reflux of gastric contents into the esophagus causing troublesome symptoms (≥2 episodes/week) or mucosal injury (erosive esophagitis, Barrett esophagus, stricture).

Epidemiology and burden:

Pathophysiology pearls:

When to suspect GERD in clinic:

Step 3 management: In a patient ≤60 with classic heartburn/regurgitation and no alarm features, GERD is a clinical diagnosis — start an empiric 8-week PPI trial without EGD or pH testing. Response confirms the diagnosis and guides ongoing therapy.

Board pearl: Cardiac chest pain mimics GERD frequently; in any patient ≥40 with new "heartburn" plus risk factors, rule out ACS first (ECG, troponin) before attributing chest discomfort to reflux. A PPI trial is never a substitute for ruling out coronary disease in the ED or urgent care setting.

Presentation Patterns and Key History

— Retrosternal burning rising toward the throat, sour/acidic regurgitation, water brash

— Triggered by large meals, fatty/spicy foods, citrus, chocolate, peppermint, caffeine, alcohol, late-night eating, recumbency

— Relieved (often only partially) by antacids

— Chronic cough (>8 weeks) without postnasal drip or asthma

— Hoarseness worse in the morning, globus sensation, throat clearing

— Adult-onset or poorly controlled asthma, especially nocturnal

— Dental enamel erosion (posterior surfaces), recurrent sinusitis, halitosis

— Non-cardiac chest pain after MI excluded

— Dysphagia or odynophagia

— Unintentional weight loss

— GI bleeding (hematemesis, melena, occult blood, iron-deficiency anemia)

— Persistent vomiting

— Early satiety or palpable mass

— New-onset symptoms age ≥60

— Family history of upper GI malignancy

— Any of these → prompt EGD, not empiric PPI

— Symptom frequency (episodes/week), nocturnal vs daytime, duration

— Prior trials of antacids, H2 blockers, PPIs — dose, duration, response

— Medication review for offending agents (CCBs, nitrates, anticholinergics, opioids, oral bisphosphonates, doxycycline, KCl, iron, NSAIDs)

— Tobacco, alcohol, BMI, dietary timing, recumbency habits

— Comorbidities: scleroderma, diabetes (gastroparesis), pregnancy, sleep apnea

Typical symptom cluster:

Atypical and extraesophageal presentations:

Alarm ("red flag") features that change the pathway entirely — memorize:

History elements to document:

Key distinction: Dyspepsia (epigastric pain, fullness, early satiety) is the dominant complaint pointing toward PUD or functional dyspepsia; heartburn/regurgitation points to GERD. Overlap is common, but the dominant symptom guides initial workup.

Board pearl: Symptoms that wake the patient from sleep or require nightly antacid use signal more severe disease and predict erosive esophagitis on EGD — these patients benefit from once-daily PPI from the start rather than a step-up from H2 blockers.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Tachycardia, orthostasis, or pallor → think GI bleeding from erosive esophagitis or Cameron lesions (hiatal hernia)

— Cachexia or temporal wasting → red flag for malignancy

— BMI and waist circumference: central obesity is a modifiable driver

— Dental enamel erosion on lingual/posterior tooth surfaces (acid exposure)

— Erythematous posterior pharynx, cobblestoning, vocal cord changes on indirect view (laryngopharyngeal reflux)

— Halitosis

— Auscultate carefully — wheezing may reflect reflux-triggered asthma

— Always assess for cardiac etiology of chest pain: murmurs, S4, JVD, peripheral edema

— Epigastric tenderness is nonspecific; presence raises suspicion for PUD or gastritis

— Palpable epigastric mass, hepatomegaly, supraclavicular (Virchow) or periumbilical (Sister Mary Joseph) nodes → gastric malignancy workup

— Succussion splash → gastric outlet obstruction or gastroparesis

— Sclerodactyly, telangiectasias, Raynaud → systemic sclerosis with severe reflux from absent LES tone and dysmotility

— Hypotension, tachycardia, melena, hematemesis → ED for resuscitation, IV PPI, urgent EGD

— Significant weight loss with anemia → expedited GI referral within 1–2 weeks

General exam is usually normal in uncomplicated GERD — the value of the exam is to identify complications, mimics, and contributing comorbidities.

Vital signs and general appearance:

HEENT:

Cardiopulmonary:

Abdominal exam:

Skin/MSK:

Hemodynamic red flags requiring same-day escalation:

CCS pearl: On the CCS simulation, an outpatient with "heartburn" plus tachycardia and conjunctival pallor should trigger CBC, type and screen, IV access, and urgent GI consult before any PPI trial — the case is bleeding until proven otherwise.

Board pearl: Dental erosion is a tell-tale physical finding that frequently anchors the GERD diagnosis on Step 3 vignettes when the symptom history is vague.

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— CBC — screen for iron-deficiency anemia (chronic GI blood loss, malignancy)

— CMP — baseline for PPI use (Mg, Cr); evaluates hepatic causes of dyspepsia

— H. pylori testing (urea breath test or stool antigen) if dyspepsia predominates or PPI-refractory — hold PPI ≥2 weeks before testing to avoid false negatives

— Lipase if epigastric pain radiating to back

— Fecal occult blood if anemia or alarm features

— Always in patients ≥40 with chest pain, even if "burning" in quality, before labeling as GERD

— Diabetics, women, and elderly often present atypically with ACS

— Barium swallow is not first-line for GERD diagnosis but useful for evaluating dysphagia (rings, strictures, achalasia, large hiatal hernia) when EGD is contraindicated or delayed

— CT abdomen if mass, perforation, or alternative intra-abdominal pathology suspected

— Gastric emptying study if gastroparesis suspected (diabetic, refractory symptoms)

— Routine EGD in young patients with classic symptoms and no alarms (low yield, costly)

— Ambulatory pH monitoring as first test — reserved for refractory or atypical cases

Uncomplicated, classic GERD requires NO testing — diagnosis is clinical, and an empiric PPI trial is both diagnostic and therapeutic.

When to order initial testing: alarm features, atypical presentation, treatment failure, or concern for alternative diagnosis.

Targeted initial labs:

ECG and troponin:

Imaging — limited role:

What NOT to order routinely:

Step 3 management: A 45-year-old with new heartburn, no alarms, on no offending meds → start empiric once-daily PPI × 8 weeks before meals and reassess. No EGD, no pH probe, no barium study at this stage.

Board pearl: The single most common Step 3 error is ordering EGD in a young patient with classic uncomplicated GERD — high-value care is the empiric trial. Conversely, failing to test for H. pylori in a patient with refractory dyspepsia/GERD is the second most common error.

Diagnostic Workup — Advanced or Confirmatory Studies

— Indications: alarm features; new symptoms age ≥60; PPI-refractory symptoms after optimized twice-daily therapy ×8 weeks; screening for Barrett esophagus in high-risk patients (chronic GERD ≥5 yr plus ≥2 of: age >50, male, white, obesity, smoking, family history of Barrett/esophageal adenocarcinoma)

— Findings: erosive esophagitis (Los Angeles grade A–D), stricture, Barrett metaplasia, hiatal hernia, eosinophilic esophagitis (rings, furrows — biopsy required)

— Biopsies of distal esophagus mandatory if salmon-colored mucosa suggests Barrett; multilevel biopsies if EoE suspected

— Gold standard for confirming pathologic acid exposure

— Indications: persistent symptoms despite PPI with normal EGD (to prove or refute GERD), pre-antireflux surgery evaluation, atypical/extraesophageal symptoms

— Test off PPI (7 days) when establishing diagnosis; on PPI when assessing adequacy of acid suppression in refractory cases

— Not for diagnosing GERD itself

— Required before antireflux surgery to exclude achalasia, scleroderma esophagus, or ineffective motility that would contraindicate fundoplication

— Detects non-acid (weakly acidic) reflux, useful in PPI-refractory symptoms

— Gastric emptying scintigraphy for suspected gastroparesis

— Laryngoscopy for LPR symptoms (low specificity)

Upper endoscopy (EGD) — the workhorse advanced test:

Ambulatory esophageal pH monitoring (24-hr catheter or 48–96-hr wireless Bravo capsule):

Esophageal manometry:

Impedance-pH testing:

Specialty studies:

Key distinction: Erosive esophagitis on EGD = confirmed GERD, no pH study needed. Normal EGD with persistent symptoms = need pH/impedance testing to differentiate true NERD (non-erosive reflux disease), reflux hypersensitivity, and functional heartburn — these have very different management trajectories.

Board pearl: Always obtain manometry before Nissen fundoplication — operating on an undiagnosed achalasia patient is a classic malpractice/board trap.

Risk Stratification or First-Line Management Logic

— Alarms present → EGD first, do not start with empiric PPI alone (though PPI may be initiated concurrently)

— No alarms → proceed to lifestyle + empiric PPI

— Weight loss if BMI elevated — strongest evidence of any lifestyle intervention

— Elevate head of bed 6–8 inches (blocks under bedposts, not just extra pillows) for nocturnal symptoms

— Avoid recumbency for 3 hours after meals; no late-night eating

— Smoking cessation, alcohol moderation

— Identify and limit personal trigger foods (individualized; routine blanket dietary restriction has weak evidence)

— Review and substitute offending medications when feasible

— Mild/intermittent symptoms (<2×/week): as-needed antacids (calcium carbonate, alginate) or H2 receptor antagonist (famotidine)

— Frequent symptoms (≥2×/week) or moderate-severe: once-daily PPI before breakfast × 8 weeks

— Partial response: confirm timing (30–60 min before meal), increase to twice-daily PPI, add bedtime H2RA for nocturnal breakthrough

— No response after 8 weeks of optimized twice-daily PPI: refractory GERD → EGD + pH/impedance testing, consider alternative diagnoses

— Erosive esophagitis (LA grade C/D) or Barrett: indefinite daily PPI

— NERD or mild erosive disease: attempt step-down to lowest effective dose, on-demand, or H2RA

Step 1 — Triage by alarm features:

Step 2 — Lifestyle and behavioral modification (always, regardless of pharmacology):

Step 3 — Pharmacologic stepwise approach:

Step 4 — Maintenance strategy after symptom control:

Step 3 management: A patient with classic GERD responding to 8 weeks of omeprazole → attempt step-down, not indefinite full-dose continuation, unless erosive esophagitis or Barrett is documented. Step-down is a high-yield value-based care answer.

Board pearl: Lifestyle alone rarely controls moderate-severe GERD, but head-of-bed elevation + weight loss are the two interventions with the strongest evidence and should appear in every management answer.

Pharmacotherapy — First-Line Drug Regimen

— Onset minutes, duration 1–2 hours

— Use: mild, infrequent, on-demand symptoms; pregnancy first-line

— Avoid sodium bicarbonate (sodium load); avoid magnesium in CKD

— Reduce gastric acid via H2 blockade; onset 30–60 min, duration 4–10 hours

— Use: mild-moderate GERD, nocturnal breakthrough on PPI, on-demand

— Tachyphylaxis develops within 2–6 weeks — limits use as monotherapy for chronic disease

— Cimetidine: many drug interactions (CYP450 inhibition), gynecomastia — avoid; famotidine preferred

— Renal dose adjustment required

— First-line for moderate-severe or frequent GERD, erosive esophagitis, Barrett

— Mechanism: irreversible inhibition of H+/K+-ATPase on parietal cells

— Dosing pearl: take 30–60 minutes before the first meal of the day (activates proton pumps); dexlansoprazole's dual-release allows mealtime-independent dosing

— Standard 8-week course; reassess and step down

— Twice-daily dosing (before breakfast and dinner) for partial responders or erosive esophagitis grade C/D

— Sucralfate: mucosal coat; safe in pregnancy

— Alginate (e.g., Gaviscon): forms raft over gastric contents; useful adjunct for postprandial/regurgitation

— Baclofen: reduces TLESRs; off-label for refractory reflux

— Prokinetics (metoclopramide): limited role; only if documented gastroparesis — risk of tardive dyskinesia (black box)

— Generally well-tolerated; observed (mostly associational) risks: C. difficile, community-acquired pneumonia, hypomagnesemia, B12 deficiency, hip fracture, AKI/interstitial nephritis, possible CKD progression, enteric infections

— Use lowest effective dose; do not stop indefinite PPI in patients with Barrett or severe erosive disease just because of these associations

Antacids (calcium carbonate, magnesium hydroxide, aluminum hydroxide, alginate):

H2 receptor antagonists (famotidine, cimetidine, nizatidine):

Proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole):

Adjuncts:

PPI long-term safety counseling:

Board pearl: A patient on PPI complaining of muscle cramps, tetany, or arrhythmia → check magnesium; chronic PPI use is a classic cause of hypomagnesemia, often with secondary hypocalcemia and hypokalemia.

Procedures / Revascularization / Invasive Management (or expanded pharmacology if non-procedural)

— Documented GERD (pH-proven or erosive esophagitis on EGD) plus one of:

— Patient preference to discontinue lifelong PPI

— Inadequate symptom control on optimized medical therapy

— Large hiatal hernia with mechanical regurgitation/volume reflux

— PPI intolerance or significant adverse effects

— Preoperative workup mandatory: EGD, manometry (rule out achalasia/scleroderma), ambulatory pH testing, often gastric emptying study

— Laparoscopic Nissen fundoplication (360° wrap) — gold standard; effective but ~20% develop dysphagia, gas-bloat syndrome, inability to belch/vomit

— Toupet (270° posterior) or Dor (180° anterior) partial fundoplication — preferred when esophageal motility is borderline to reduce dysphagia

— Magnetic sphincter augmentation (LINX device) — ring of magnetic beads around LES; outcomes comparable to Nissen with less gas-bloat; contraindicated with large hiatal hernia (>3 cm) or severe esophagitis

— Roux-en-Y gastric bypass — best antireflux operation in patients with obesity (BMI ≥35); addresses GERD and weight simultaneously. Sleeve gastrectomy worsens GERD — avoid in GERD patients seeking bariatric surgery.

— Transoral incisionless fundoplication (TIF), Stretta radiofrequency — modest efficacy; niche role

— Peptic stricture: endoscopic dilation + indefinite PPI

— Barrett esophagus:

— No dysplasia: surveillance EGD every 3–5 years

— Low-grade dysplasia: endoscopic eradication therapy (radiofrequency ablation) preferred over surveillance

— High-grade dysplasia or intramucosal adenocarcinoma: endoscopic mucosal resection + ablation

— Esophageal adenocarcinoma: staging, multidisciplinary oncology

Indications for antireflux procedure referral:

Surgical options:

Endoscopic options (selected centers):

Treatment of GERD complications:

Step 3 management: Obese patient (BMI 42) with severe GERD considering surgery → recommend Roux-en-Y gastric bypass over fundoplication or sleeve. This is a frequently tested high-yield answer integrating bariatric and GI logic.

Board pearl: Pre-fundoplication manometry showing aperistalsis = scleroderma esophagus → fundoplication is contraindicated (would produce severe dysphagia).

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of erosive esophagitis with less severe symptoms — pain perception blunted; complications often present first (anemia, dysphagia, weight loss)

— Lower threshold for EGD given higher malignancy risk and atypical presentations

— Polypharmacy review essential — discontinue or substitute offending agents: CCBs, nitrates, anticholinergics, bisphosphonates, opioids

— Oral bisphosphonates: counsel to remain upright 30–60 minutes after dose with full glass of water; switch to IV zoledronic acid if erosive esophagitis develops

— PPI risks magnified: hypomagnesemia, C. difficile, fracture, B12 deficiency, drug interactions (clopidogrel — prefer pantoprazole or rabeprazole over omeprazole/esomeprazole)

— Deprescribing: in elderly without erosive disease or Barrett, attempt PPI taper after symptom control; abrupt cessation causes rebound hyperacidity — taper over 2–4 weeks or bridge with H2RA

— PPIs do not require dose adjustment but observe for AKI/acute interstitial nephritis (presents as eosinophilia, sterile pyuria, rising Cr weeks to months after initiation) — discontinue PPI if suspected

— Associational data link chronic PPI use to CKD progression — use lowest effective dose

— H2RAs (famotidine) require renal dose reduction at CrCl <50 — can cause confusion, thrombocytopenia in elderly with CKD

— Avoid magnesium- and aluminum-containing antacids in advanced CKD

— PPIs metabolized via CYP2C19/3A4 — reduce dose in severe cirrhosis (especially omeprazole, esomeprazole)

— PPI use in cirrhosis is associated with spontaneous bacterial peritonitis and hepatic encephalopathy — prescribe only with clear indication, reassess regularly

— Avoid metoclopramide in advanced hepatic disease (risk of EPS and encephalopathy)

Elderly patients (≥65):

Renal impairment (CKD):

Hepatic impairment:

Step 3 management: An elderly patient on chronic omeprazole presents with new fatigue and macrocytic anemia → check B12; PPI-induced B12 deficiency from impaired protein-bound B12 release is a board-favorite.

Board pearl: Rising creatinine + eosinophiluria in a patient months into a PPI = acute interstitial nephritis → discontinue PPI promptly.

Special Populations — Pregnancy, Pediatrics, or Other Demographic Subgroups

— GERD affects up to two-thirds of pregnancies; due to progesterone-mediated LES relaxation and mechanical pressure from gravid uterus

— Symptoms typically resolve postpartum

— Stepwise therapy:

— First-line: lifestyle modification (small frequent meals, avoid recumbency, head-of-bed elevation, avoid triggers)

— Second-line: calcium- or magnesium-based antacids (avoid sodium bicarbonate — alkalosis, fluid retention; avoid magnesium near term — tocolytic effect); sucralfate is safe (minimal systemic absorption) and a good early option

— Third-line: H2RAs — famotidine preferred; cimetidine avoided (antiandrogenic)

— Fourth-line: PPIs if needed — all generally considered safe in pregnancy; omeprazole was historically category C, others B; current ACOG/ACG guidance supports PPI use when benefits outweigh risks

— Avoid misoprostol (abortifacient)

— Antacids, sucralfate, famotidine, and most PPIs (pantoprazole, omeprazole) are compatible with breastfeeding

— Infants: physiologic regurgitation common, usually resolves by 12–18 months — reassurance, smaller more frequent feeds, upright positioning after feeds, thickened feeds

— Avoid acid suppression in uncomplicated infant reflux (increases risk of LRTI and gastroenteritis)

— Pathologic GERD in children: failure to thrive, recurrent aspiration, esophagitis → pediatric GI referral, consider PPI

— Adolescents: management mirrors adults; rule out eosinophilic esophagitis in atypical or PPI-refractory cases

— Severe GERD from absent LES tone and aperistaltic esophagus

— Aggressive twice-daily PPI indefinitely; fundoplication contraindicated (causes dysphagia)

— Weight loss is the single most effective non-pharmacologic intervention

— Consider Roux-en-Y bypass for combined bariatric/antireflux indication

Pregnancy:

Lactation:

Pediatrics:

Patients with scleroderma/CREST:

Patients with obesity:

Step 3 management: Pregnant patient at 20 weeks with persistent heartburn unresponsive to antacids → start famotidine; escalate to PPI only if H2RA inadequate. Reassure that symptoms typically resolve postpartum.

Board pearl: Healthy infant "spitter" gaining weight normally needs reassurance, not ranitidine or PPI — overtreatment of physiologic reflux is a tested error.

Complications and Adverse Outcomes

— Mucosal breaks on EGD; graded LA classification A (smallest) to D (confluent circumferential)

— Severe grades (C/D) → indefinite PPI; repeat EGD to confirm healing

— Chronic inflammation → fibrosis → progressive solid-food dysphagia

— Treat with endoscopic dilation + indefinite PPI to prevent recurrence

— Metaplasia from squamous to intestinal columnar epithelium at the GE junction

— Prevalence ~10% of chronic GERD patients

— Premalignant for esophageal adenocarcinoma (~0.1–0.3%/year progression; higher with dysplasia)

— Surveillance EGD intervals:

— Non-dysplastic Barrett: every 3–5 years

— Indefinite for dysplasia: repeat after optimized PPI 3–6 months

— Low-grade dysplasia: endoscopic eradication therapy (RFA) or annual surveillance

— High-grade dysplasia: endoscopic resection + ablation

— Incidence rising in Western populations

— Risk factors: chronic GERD, Barrett, obesity, male sex, white race, smoking

— Presents with progressive dysphagia (solids → liquids), weight loss, anemia

— Chronic laryngitis, vocal cord granulomas, dental erosion

— Reflux-triggered asthma exacerbations

— Recurrent aspiration pneumonia (especially in elderly, scleroderma, supine reflux)

— Pulmonary fibrosis association (especially in scleroderma)

— Erosive esophagitis can cause overt or occult bleeding; iron-deficiency anemia workup

— Cameron lesions: linear erosions in hiatal hernia at the diaphragmatic impression — recurrent IDA source

— PPI: hypomagnesemia, B12 deficiency, C. difficile, AIN, fracture risk, rebound hyperacidity on cessation

— Post-fundoplication: gas-bloat syndrome, dysphagia, inability to belch/vomit, wrap migration

Erosive esophagitis:

Peptic stricture:

Barrett esophagus:

Esophageal adenocarcinoma:

Extraesophageal complications:

GI bleeding:

Treatment-related complications:

Key distinction: Schatzki ring causes intermittent dysphagia to solids ("steakhouse syndrome") and is often associated with GERD/hiatal hernia — distinct from peptic stricture (progressive dysphagia from chronic inflammation). Both are treated with dilation, but Schatzki may not require chronic PPI.

Board pearl: New progressive solid-food dysphagia in a chronic GERD patient = EGD now, looking for stricture vs. adenocarcinoma — never reassure and increase PPI.

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Hematemesis, melena, hemodynamic instability → resuscitation, IV PPI infusion, urgent EGD within 24 hours

— Suspected esophageal perforation (Boerhaave): severe chest pain after vomiting, subcutaneous emphysema, fever, sepsis — surgical emergency, CT with water-soluble contrast, NPO, broad-spectrum antibiotics, thoracic surgery consult

— Food bolus impaction with inability to handle secretions → urgent EGD

— Severe aspiration pneumonia from reflux

— Any alarm feature (dysphagia, odynophagia, weight loss, anemia, persistent vomiting, age ≥60 with new symptoms, family history of upper GI cancer)

— Suspected Barrett esophagus

— PPI-refractory symptoms after 8 weeks of optimized twice-daily therapy

— Recurrent symptoms after a course of PPI in a high-risk patient

— Considering antireflux surgery

— Need for pH/impedance testing or manometry

— Surveillance EGD for known Barrett

— ENT/laryngology: chronic hoarseness, suspected laryngopharyngeal reflux, vocal cord changes

— Pulmonary: asthma exacerbations refractory to standard therapy, suspected reflux-related pulmonary disease

— Bariatric surgery: BMI ≥35 with severe GERD

— Rheumatology: scleroderma-associated reflux

— Psychiatry/behavioral: when functional heartburn or reflux hypersensitivity confirmed and SSRIs/TCAs being considered

Immediate ED referral / inpatient triage:

Urgent (1–2 week) GI referral:

Routine GI referral:

Specialty co-management:

CCS pearl: A patient with chronic GERD presenting to clinic with new melena and Hgb 8 → simulate NPO, two large-bore IVs, IV fluids, IV pantoprazole 80 mg bolus then 8 mg/hr infusion, type and screen, GI consult for urgent EGD, admit to monitored bed. Sequence and "advance clock" timing matter on CCS.

Step 3 management: Refractory GERD on twice-daily PPI for 8 weeks → next step is EGD plus ambulatory pH/impedance testing (on or off PPI per clinical question), not simply escalating to triple-daily PPI or adding metoclopramide empirically.

Key Differentials — Same-Category Causes

— Epigastric pain, often relieved (duodenal) or worsened (gastric) by food

— H. pylori or NSAID exposure; risk of bleeding, perforation

— Diagnose with EGD and H. pylori testing; treat with PPI ± eradication therapy

— Postprandial fullness, early satiety, epigastric pain/burning ≥3 months

— Normal EGD, no H. pylori, no structural cause

— Treatment: PPI trial, H. pylori eradication if positive, low-dose TCA (amitriptyline) for refractory pain-predominant

— Young adults, atopic background (asthma, eczema, allergies)

— Dysphagia to solids, food impaction; PPI-unresponsive heartburn

— EGD: rings ("trachealization"), linear furrows, white exudates; biopsy ≥15 eosinophils/HPF

— Treatment: PPI trial (some respond), topical swallowed steroids (fluticasone, budesonide slurry), dietary elimination, dupilumab for refractory

— Progressive dysphagia to both solids and liquids simultaneously, regurgitation of undigested food, weight loss

— Manometry: aperistalsis + failure of LES relaxation; "bird's beak" on barium swallow

— Treatment: pneumatic dilation, Heller myotomy, POEM

— Chest pain and dysphagia; "corkscrew" or "jackhammer" pattern

— Diagnose with manometry; treat with CCBs, nitrates, TCAs

— Diabetic or post-viral; nausea, early satiety, postprandial fullness, vomiting of undigested food hours after meals

— Gastric emptying scintigraphy diagnostic; treat with dietary modification, glycemic control, metoclopramide (short-term)

— Bisphosphonates, doxycycline, KCl, NSAIDs, iron — focal odynophagia; counsel on water + upright posture

— Candida (white plaques, immunocompromised), HSV (small discrete ulcers), CMV (large solitary ulcers in AIDS)

Peptic ulcer disease (PUD):

Functional dyspepsia:

Eosinophilic esophagitis (EoE):

Achalasia:

Esophageal spasm / hypercontractile esophagus:

Gastroparesis:

Pill esophagitis:

Infectious esophagitis:

Key distinction: EoE vs GERD — both cause heartburn and dysphagia; key clues for EoE are young male, atopy, food impactions, and PPI-refractory symptoms with characteristic EGD findings on biopsy. Always biopsy on EGD in patients with dysphagia, even if mucosa appears normal.

Key Differentials — Other-Category Causes

— Acute coronary syndrome: retrosternal pain, often described as "burning" or "indigestion," especially in women, diabetics, elderly; ECG and troponin mandatory in any patient ≥40 with new chest discomfort regardless of how "GERD-like" it sounds

— Stable angina: exertional, relieved by rest/nitrates

— Pericarditis: positional pain, pleuritic, diffuse ST elevations

— Pulmonary embolism: pleuritic chest pain, dyspnea, tachycardia, hypoxia

— Pneumonia, pleurisy: cough, fever, focal findings

— Biliary colic: RUQ/epigastric postprandial pain (especially fatty meals), radiates to right scapula

— Cholecystitis: RUQ pain, fever, Murphy sign

— Choledocholithiasis with cholangitis: Charcot triad — fever, jaundice, RUQ pain

— Acute pancreatitis: epigastric pain radiating to back, nausea/vomiting; lipase elevation

— Chronic pancreatitis: postprandial pain, steatorrhea, weight loss

— Costochondritis: reproducible chest wall tenderness

— Rib injury, intercostal strain

— Panic disorder: chest tightness, dyspnea, paresthesias, fear of dying

— Somatic symptom disorder

— Reflux hypersensitivity and functional heartburn: typical symptoms with normal pH and impedance studies — treat with neuromodulators (low-dose TCA, SSRI)

— Gastric or esophageal malignancy

— Aerophagia, rumination syndrome (regurgitation immediately after meals, no acid reflux on testing)

— Hypercalcemia (causes both GERD-like dyspepsia and PUD via gastrin elevation)

— Zollinger-Ellison syndrome: refractory PUD, severe GERD, diarrhea, hypergastrinemia off PPI

Cardiac — must exclude first:

Pulmonary:

Biliary/hepatic:

Pancreatic:

Musculoskeletal:

Psychiatric/functional:

Other GI mimics:

Endocrine/metabolic:

Step 3 management: A 55-year-old diabetic man with "heartburn" after climbing stairs, relieved by rest → rule out angina with ECG and stress testing; do not start PPI as primary therapy. Exertional "heartburn" is cardiac until proven otherwise.

Board pearl: Refractory GERD + diarrhea + multiple/recurrent ulcers → check fasting serum gastrin and secretin stimulation test for Zollinger-Ellison syndrome, often part of MEN1.

Secondary Prevention / Discharge Medications / Long-Term Plan

— Responder, mild disease: step down to lowest effective dose, on-demand PPI, or H2RA

— Responder, erosive esophagitis grade C/D or Barrett: indefinite daily PPI at lowest effective dose

— Partial responder: optimize timing, twice-daily dosing, add bedtime H2RA; if still inadequate → EGD + pH testing

— Non-responder: EGD + pH/impedance; reconsider diagnosis

— Always use the lowest effective PPI dose; reassess annually for ongoing indication

— Document indication clearly in the chart (deprescribing prompt)

— Counsel about evidence-based and associational risks

— Avoid abrupt cessation — taper over 2–4 weeks or bridge with H2RA to prevent rebound hyperacidity

— Weight management

— Head-of-bed elevation for nocturnal symptoms

— Avoid late-night meals; 3-hour interval between last meal and recumbency

— Smoking cessation, alcohol moderation

— Trigger food identification

— Periodically review for offending agents (CCBs, nitrates, anticholinergics, bisphosphonates, NSAIDs); substitute when possible

— Educate patients on bisphosphonate administration to prevent pill esophagitis

— Identify Barrett candidates (chronic GERD ≥5 yr plus risk factors) for one-time screening EGD per ACG guidance

— Maintain surveillance intervals for established Barrett

— Standard preventive care unaffected by GERD itself, but PPI users may be more susceptible to enteric and respiratory infections — emphasize influenza and pneumococcal vaccination in elderly

Define the long-term phenotype after the 8-week PPI trial:

Long-term medication strategy:

Lifestyle pillars (lifelong):

Medication reconciliation:

Cancer screening logic:

Vaccinations and comorbidity care:

Step 3 management: A patient with NERD whose symptoms resolved after 8 weeks of omeprazole → attempt step-down to on-demand PPI or switch to H2RA. Indefinite daily PPI is reserved for erosive esophagitis (grade C/D) or Barrett esophagus. This deprescribing decision is a high-yield, value-based-care Step 3 answer.

Board pearl: Document a PPI deprescribing review at every annual visit — failure to reassess chronic PPI use is a common quality-measure miss.

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Reassess symptoms at 8 weeks after starting PPI — the critical decision point

— If responding: step down and follow up in 3 months

— If not responding: optimize timing, escalate to BID PPI, recheck at 8 more weeks; if still failing → EGD + pH testing

— Annual visit to review symptoms, deprescribing opportunities, lifestyle adherence

— Barrett patients: per surveillance interval (3–5 years non-dysplastic)

— Post-fundoplication: 4–6 weeks postop for symptom assessment, dietary progression

— Magnesium if symptomatic (cramps, arrhythmia, tetany) or on diuretics

— Vitamin B12 every 1–2 years in long-term users, especially elderly

— Iron studies and CBC if any anemia signal

— Creatinine if new renal concerns (rule out AIN)

— Bone density per standard USPSTF guidelines (PPI use alone does not change screening thresholds)

— Take PPI 30–60 minutes before breakfast (and dinner if BID) — timing failure is the most common cause of "PPI failure"

— Adherence: many patients self-discontinue when symptoms improve; explain healing vs symptom control

— Lifestyle reinforcement at every visit

— Smoking cessation counseling — pharmacotherapy and behavioral support

— Weight management — connect to dietitian or structured program when BMI elevated

— Sleep hygiene counseling — nocturnal reflux disrupts sleep architecture and predicts complications

— Stress and anxiety management — overlap with functional heartburn

— Voice rest and ENT follow-up for laryngopharyngeal reflux

— Provide written trigger food and lifestyle handouts

— Discuss when to call: new dysphagia, weight loss, black stools, vomiting blood

Initial follow-up cadence:

Long-term follow-up:

Monitoring labs (for chronic PPI use, individualized — not routinely required by guidelines but reasonable):

Counseling priorities:

Rehab/quality of life:

Patient education resources:

Step 3 management: A patient returning at 8 weeks reporting "PPI didn't work" — first ask when they take it. If taken with or after meals, fix timing before declaring treatment failure. This is a classic high-yield Step 3 vignette.

CCS pearl: On the CCS interface, schedule the 8-week recheck visit when starting empiric PPI — the simulation rewards appropriate follow-up planning.

Ethical, Legal, and Patient Safety Considerations

— Chronic PPI therapy requires discussion of benefits (symptom control, complication prevention) and potential risks (associational data on fracture, C. difficile, B12 deficiency, AIN, hypomagnesemia); document the conversation

— Antireflux surgery: detailed informed consent including dysphagia (5–10%), gas-bloat, recurrence (up to 30% at 10 years), and need for repeat surgery in subset

— Barrett surveillance vs endoscopic eradication: discuss progression risk, procedural risk, cost, and patient values

— Inadvertent PPI continuation after hospitalization is a major polypharmacy problem — stress ulcer prophylaxis started in ICU is frequently never deprescribed. Reconcile PPI at every transition (discharge, primary care handoff, nursing home transfer)

— Conversely, abrupt discontinuation of indicated PPI (e.g., Barrett patient) at transition can lead to rebound and complications — explicit handoff documentation needed

— Bisphosphonate counseling errors → preventable pill esophagitis and even perforation

— Anchoring bias: labeling chest pain as "GERD" without ruling out ACS is a high-stakes, frequently-litigated error in ambulatory and ED settings

— Failing to perform EGD in alarm-feature patients delays cancer diagnosis — missed Barrett-to-adenocarcinoma progression is a malpractice theme

— OTC PPIs are widely available — patients may self-treat for years without medical evaluation, masking malignancy. Ask explicitly about OTC use during history-taking

— Cost: generic omeprazole/pantoprazole are inexpensive; brand-name esomeprazole/dexlansoprazole add cost without major clinical benefit for most patients

— Deprescribing chronic PPI when not indicated is a Choosing Wisely / ABIM Foundation recommendation

— Avoid empiric EGD in young patients with classic uncomplicated GERD (low-value care)

— Not directly applicable to GERD, but esophageal cancer diagnosis triggers cancer registry reporting

Informed consent and shared decision-making:

Patient safety / transition-of-care risks:

Diagnostic safety:

Health equity and access:

Quality and value-based care:

Mandatory reporting / public health:

Step 3 management: At hospital discharge, a patient started on pantoprazole for stress ulcer prophylaxis in the ICU without an ongoing indication should have the PPI discontinued at discharge with clear documentation. Continuing it indefinitely is a tested patient safety / quality-of-care error.

Board pearl: Always document the indication and planned duration for any chronic acid suppression — the absence of these is the single most common deprescribing failure point.

High-Yield Associations and Rapid-Fire Clinical Facts

— TLESRs (not low LES tone) cause most reflux

— Hiatal hernia disrupts crural diaphragm contribution to LES

— Scleroderma causes severe GERD via aperistalsis + absent LES tone

— Classic symptoms + no alarms = empiric PPI, no testing

— Hold PPI ≥2 weeks before H. pylori testing (false negatives)

— Manometry mandatory before fundoplication to exclude achalasia/scleroderma

— Test pH off PPI to diagnose GERD; on PPI to assess adequacy of acid suppression

— PPI 30–60 min before breakfast; bad timing is the #1 cause of "PPI failure"

— Pantoprazole or rabeprazole preferred with clopidogrel (less CYP2C19 interaction)

— Famotidine preferred over cimetidine (interactions, gynecomastia)

— Roux-en-Y gastric bypass is the best antireflux operation in obese patients

— Sleeve gastrectomy worsens GERD — avoid

— Progressive solid-food dysphagia + chronic GERD → EGD now (stricture vs adenocarcinoma)

— Barrett: salmon-colored mucosa proximal to GE junction with intestinal metaplasia on biopsy

— Esophageal adenocarcinoma > squamous cell in chronic GERD patients

— Schatzki ring: intermittent solid-food dysphagia ("steakhouse syndrome")

— Hypomagnesemia → tetany, arrhythmia

— B12 deficiency → macrocytic anemia, neuropathy

— AIN → rising Cr + eosinophilia/eosinophiluria

— C. difficile, CAP, fracture risk (associational)

— SBP and hepatic encephalopathy in cirrhosis

— Rebound hyperacidity on abrupt cessation

— Lifestyle → antacids/sucralfate → famotidine → PPI

— Avoid cimetidine (antiandrogenic) and misoprostol

Mechanism pearls:

Diagnostic pearls:

Treatment pearls:

Complication pearls:

PPI adverse effect pearls:

Pregnancy pearls:

Pediatric pearl: Healthy "spitter" infant gaining weight = reassurance, not acid suppression

Zebra: Zollinger-Ellison — refractory GERD + ulcers + diarrhea; check fasting gastrin off PPI

Board pearl: A young atopic male with food impaction, dysphagia, PPI-refractory heartburn, and EGD showing rings/furrows = eosinophilic esophagitis — biopsy showing ≥15 eos/HPF is diagnostic.

Key distinction: Barrett = metaplasia (premalignant); erosive esophagitis = inflammation (reversible with PPI). Both need PPI, but only Barrett triggers indefinite therapy plus surveillance.

Board Question Stem Patterns

— 38-year-old with 3 months of postprandial heartburn, no alarms, BMI 31

— Answer: lifestyle modification + empiric once-daily PPI × 8 weeks; not EGD, not pH testing

— 62-year-old with new heartburn and 10-lb weight loss, or progressive solid-food dysphagia, or iron-deficiency anemia

— Answer: EGD now, not empiric PPI alone

— Patient on omeprazole 20 mg "with breakfast" still symptomatic

— Answer: fix timing first (30–60 min before breakfast) before escalating dose or pursuing further workup

— Chronic PPI user with muscle cramps, prolonged QT, low Mg → PPI-induced hypomagnesemia

— Chronic PPI user with rising Cr + eosinophiluria → acute interstitial nephritis

— Elderly PPI user with macrocytic anemia → B12 deficiency

— 58-year-old diabetic with exertional "heartburn" relieved by rest

— Answer: ECG + troponin + stress testing, not PPI

— 24-week pregnant patient with heartburn unresponsive to antacids

— Answer: famotidine, then PPI if needed

— Patient with known non-dysplastic Barrett on optimized PPI

— Answer: surveillance EGD every 3–5 years; low-grade dysplasia → endoscopic eradication therapy preferred

— BMI 42 patient with severe GERD considering surgery

— Answer: Roux-en-Y gastric bypass, not sleeve, not fundoplication

— Young atopic male with food impaction, dysphagia, normal pH study

— Answer: EGD with biopsy (rings, furrows; ≥15 eos/HPF)

— Refractory GERD + multiple ulcers + diarrhea

— Answer: fasting gastrin off PPI, secretin stimulation test

— NERD patient asymptomatic after 8 weeks of PPI

— Answer: step down, not continue indefinitely

Pattern 1 — Classic uncomplicated GERD:

Pattern 2 — Alarm feature trap:

Pattern 3 — Refractory symptoms:

Pattern 4 — PPI complications:

Pattern 5 — Cardiac mimic:

Pattern 6 — Pregnancy:

Pattern 7 — Barrett surveillance:

Pattern 8 — Bariatric decision:

Pattern 9 — EoE clue:

Pattern 10 — Zollinger-Ellison clue:

Pattern 11 — Deprescribing:

Step 3 management: Discharge after ICU stay — review the medication list and stop stress-ulcer prophylaxis PPI if no ongoing indication; this is a frequently tested transition-of-care safety question.

One-Line Recap

In a patient with classic heartburn/regurgitation and no alarm features, GERD is a clinical diagnosis treated with lifestyle modification plus an empiric 8-week once-daily PPI taken 30–60 minutes before breakfast, followed by step-down to the lowest effective dose — while any alarm feature (dysphagia, weight loss, GI bleeding, persistent vomiting, age ≥60, family history of upper GI cancer) mandates prompt EGD.

— Diagnostic algorithm: classic symptoms + no alarms → empiric PPI; alarms or refractory symptoms → EGD ± pH/impedance ± manometry. Hold PPI ≥2 weeks before H. pylori testing.

— Pharmacotherapy: PPI is first-line for moderate-severe GERD; timing (pre-breakfast) and adherence drive efficacy. Step down NERD; continue indefinitely for erosive esophagitis grade C/D and Barrett. Famotidine preferred among H2RAs; bedtime H2RA for nocturnal breakthrough. Lifestyle (weight loss, head-of-bed elevation, no late meals, smoking cessation) is foundational and lifelong.

— Complications and surveillance: progressive solid-food dysphagia in chronic GERD = EGD now (stricture vs adenocarcinoma). Barrett surveillance every 3–5 years if non-dysplastic; endoscopic eradication therapy for low-grade dysplasia. Monitor for PPI-related hypomagnesemia, B12 deficiency, AIN, and C. difficile.

— Special populations and safety: pregnancy stepwise (lifestyle → antacids/sucralfate → famotidine → PPI; avoid cimetidine and misoprostol); obese GERD candidates for bariatric surgery → Roux-en-Y bypass, not sleeve; scleroderma → indefinite BID PPI, no fundoplication. Always rule out ACS before labeling chest pain as GERD, reconcile and deprescribe PPIs at every transition of care, and never miss alarm features in a patient ≥60 or with anemia, dysphagia, or weight loss.

High-yield recap bullets:

Board pearl: The two most-tested errors are (1) ordering EGD in a young classic-symptom patient (overuse) and (2) failing to order EGD in an alarm-feature patient (underuse) — know both extremes cold.